CT041 TRIAL STATUS
The U.S. CT041 trial is active but no longer recruiting. What now?
CT041 is the investigational code used in the trial that led to satri-cel’s approval in China. The North American study is currently listed as active, not recruiting. That is not the same as saying no U.S. treatment or trial option exists.
What NCT04404595 Is
NCT04404595 is the registered North American clinical trial of CT041 (satri-cel) in advanced gastric and gastro-oesophageal junction cancer. ClinicalTrials.gov currently lists its status as active, not recruiting, meaning the study is ongoing for enrolled patients but closed to new participants.
What Active, Not Recruiting Actually Means
A closed enrollment window does not mean the underlying treatment concept has failed, and it does not mean a satri-cel pathway is automatically the next step. It means this specific study is not currently accepting new patients.
The Local-Standard and Local-Trial Screen Comes First
Before any China pathway is discussed, Vialen requires a current review of local standard-of-care options and any other open clinical trial for which the case may qualify. A closed trial does not replace this step.
When Commercial Satri-cel Review May Become Relevant
For a clinically appropriate, later-line, CLDN18.2-positive, HER2-negative case with no clearly preferable feasible local standard or trial remaining, a structured review of commercial satri-cel treatment in China may become relevant. This is a case-by-case clinical determination, not an automatic next step.